 In addition, the following FDA text regarding the risk of developing fibrosarcomas will be discussed with all participating subjects In a 2-year repeat subcutaneous dose carcinogenicity study of liraglutide injected once a day in CD-1 mice, a treatment-related increase in fibrosarcomas was seen on the dorsal skin and subcutis, the body surface used for drug injection, in males in the 3 mgkgday group. These fibrosarcomas were attributed to the high local concentration of drug near the injection site. The liraglutide concentration in the clinical formulation 6 mgmL is 10 times higher than the concentration in the formulation used to administer 3 mgkgday liraglutide to mice in the carcinogenicity study 0.6 mgmL. 